OncoMatch/Clinical Trials/NCT04615143
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Is NCT04615143 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Tislelizumab combined with Levatinib for recurrent hepatocellular carcinoma.
Treatment: Tislelizumab · Tislelizumab combined with Levatinib — This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: curative ablation
Diagnosed as recurrent hepatocellular carcinoma after curative treatment
Cannot have received: transarterial chemoembolization
Previously received any transarterial chemoembolization
Cannot have received: immunotherapy
Previously received any...immune therapy
Cannot have received: other local or systemic liver cancer treatments
Exception: except for curative ablation
Previously received any...other local or systemic liver cancer treatments, except for curative ablation
Lab requirements
Liver function
child-pugh score 5-7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify